Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study

[1]  J. Ingram.  The epidemiology of hidradenitis suppurativa * , 2020, The British journal of dermatology.

[2]  G. Jemec,et al.  Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  T. Braunberger,et al.  Emerging medical treatments for hidradenitis suppurativa. , 2020, Journal of the American Academy of Dermatology.

[4]  A. Kimball,et al.  Biologic therapies for the treatment of hidradenitis suppurativa , 2020, Expert opinion on biological therapy.

[5]  A. Gottlieb,et al.  Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial. , 2020, Journal of the American Academy of Dermatology.

[6]  G. Jemec,et al.  Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa. , 2019, JAMA dermatology.

[7]  A. Garg,et al.  All-Cause Mortality Among Patients with Hidradentitis Suppurativa: a population-based cohort study in the United States. , 2019, Journal of the American Academy of Dermatology.

[8]  A. Gottlieb,et al.  Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa , 2019, The British journal of dermatology.

[9]  D. Hevey,et al.  A qualitative analysis of psychological distress in hidradenitis suppurativa , 2019, The British journal of dermatology.

[10]  A. Cartron,et al.  Comorbidities of hidradenitis suppurativa: A review of the literature , 2019, International journal of women's dermatology.

[11]  F. Blanco-Favéla,et al.  Role of interleukin‐17 in acute myocardial infarction , 2019, Molecular immunology.

[12]  Juan Zhou,et al.  IL‐17A contributes to myocardial ischemic injury by activating NLRP3 inflammasome in macrophages through AMPK&agr;/p38MAPK/ERK1/2 signal pathway in mice , 2019, Molecular immunology.

[13]  S. Thomsen,et al.  Hidradenitis Suppurativa: Causes, Features, and Current Treatments. , 2018, The Journal of clinical and aesthetic dermatology.

[14]  J. Merola,et al.  Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis , 2018, Journal of the American Academy of Dermatology.

[15]  L. Schmitz,et al.  A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa , 2018, JAMA dermatology.

[16]  G. Jemec,et al.  Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities , 2018, The British journal of dermatology.

[17]  G. Jemec,et al.  Hidradenitis Suppurativa: Advances in Diagnosis and Treatment , 2017, JAMA.

[18]  C. Rodríguez,et al.  The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa , 2017, Mediators of inflammation.

[19]  J. Sánchez-Payá,et al.  Assessment of subclinical atherosclerosis in hidradenitis suppurativa , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.

[21]  G. Gislason,et al.  Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. , 2016, JAMA dermatology.

[22]  I. Hamzavi,et al.  Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[23]  P. Wolkenstein,et al.  Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta‐analysis of observational studies , 2015, The British journal of dermatology.

[24]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  S. Halevy,et al.  Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  R. Balicer,et al.  [The quality indigators program in Clalit Health Services: the first decade]. , 2010, Harefuah.

[27]  K. Radcliffe,et al.  Hidradenitis suppurativa. , 1991, Genitourinary medicine.

[28]  J. Ingram.  The Genetics of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[29]  Do,et al.  Biologic Therapies in the Treatment of Hidradenitis Suppurativa , 2010 .

[30]  P P Coulter,et al.  The first decade. , 1969, Arizona medicine.